Study objective-There is little information on the potential benefit of immunising all patients with chronic lung disease in the community against influenza. The clinical eVectiveness and economic benefit was established of the influenza vaccination programme in a general practice based cohort of adult patients with chronic lung disease followed up during the 1995/96 influenza A epidemic. Design-A prospective cohort study from October 1995 to March 1996. Setting-The study was undertaken in the Utrecht General Practices Network with six large group practices, covering a total population of approximately 50 000 patients in the Netherlands. Patients-Computerised medical records of 1696 patients with chronic lung disease aged over 18 years with an indication for vaccination according to the Dutch GP guidelines were reviewed. Main results-The overall attack rate of any complication, including all cause death, low respiratory tract infection, and acute cardiac disease was 15%. Exacerbations of lung disease were most frequent (13%). Death, pneumonia, and acute cardiac disease were mainly limited to patients >65 years. No eVectiveness of the immunisation programme could be established in patients 18-64 years (n=1066), after controlling for baseline prognosis in multivariable logistic regression analysis. In vaccinees >65 years (n=630), the occurrence of any complication was reduced by 50% (95% CI 17, 70%). The economic benefit was estimated at £50 per elderly vaccinee. Conclusions-This study suggests that in the Netherlands immunisation of elderly patients with chronic lung disease against influenza is eVective and cost-saving, hence these patients should be given high priority. More, preferably experimental, studies are needed to establish whether adult lung patients under 65 years in the community will also benefit from vaccination.
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Although annual influenza vaccination has been recommended to all patients with chronic pulmonary disease, 1 immunisation rates remain low, particularly in patients under 65. [2] [3] [4] These low rates may only be partly the result of concerns about side eVects, because many studies have shown no serious adverse events. [5] [6] [7] [8] Scepticism about the impact of influenza in non-institutionalised patients with chronic lung disease is more likely to play an important part. Currently, little information is available on influenza related mortality and morbidity in this group. 9 Several studies have reported on the eVectiveness of influenza vaccination, but most were confined to elderly subjects with or without chronic medical conditions. [10] [11] [12] [13] [14] [15] [16] Only a few studies included younger adults, and none considered the eVectiveness in patients with chronic lung disease alone. [17] [18] [19] This apparent lack of evidence of the potential health and economic benefit resulting from immunising all patients with chronic lung disease in the community against influenza may explain the poor immunisation rates. 9 20 We aimed to assess the clinical eVectiveness of an influenza vaccination programme in preventing complications in adult patients with chronic pulmonary disease. We therefore prospectively followed up a general practice based cohort of patients with lung disease from the moment of vaccination until the end of the influenza A epidemic of 1995/96. Because an age based immunisation policy was recently introduced in the Netherlands, after many other countries, 21 we considered its eVectiveness in patients aged under and those aged over 65 years. Finally, we estimated direct costs of medical care associated with the influenza epidemic and immunisation programme.
Methods

SETTING AND STUDY SUBJECTS
The Utrecht University General Practices Network consists of six computerised group practices employing 23 general practitioners (GPs), and covering about 50 000 patients living in the central part of the Netherlands. Since 1989, clinical diagnoses and drug prescriptions have been registered in the medical records using ICPC codes, 22 according to the ICHPPC-2 criteria, 23 and ATC codes, 24 respectively. Anonymous data were stored in a central database. The initial step in the enrolment procedure consisted of a computerised search of all potential patients with chronic lung disease in the period October 1993 to October 1995 using a software selection module. 25 The search was based on the following diagnoses: COPD (chronic bronchitis/brochiectasis and emphysema), asthma, malignant and benign neoplasm of the bronchus/lung, tuberculosis, pleurisy, congenital anomalies, and other diseases of the respiratory system. In addition, patients with drug prescriptions from the ATCsubcategory R03 (adrenergics/other antiasthmatics) or with a "lung tag" indicating chronic lung disease only were selected. Participating GPs subsequently classified each initially selected patient as indicated for vaccination or not according to the guidelines of the Dutch College of General Practitioners. 26 All selected high risk study subjects were invited for vaccination in writing. Patients under 18 years with asthma were not part of our study domain. Both risk of influenza related complications and vaccine eVectiveness are diVerent from that of adult patients with lung disease. The influenza epidemic started in week 46 (1995) and ended in week 10 (1996) . 28 The first and most important peak of influenza activity was observed in December/January and was associated with isolates of influenza A(H3N2), whereas the second peak in February was small and mainly associated with influenza A(H1N1) isolates. The vaccine composition largely matched viral strains isolated from clinical samples collected by the Dutch Sentinel Practice network. 28 
DATA COLLECTION
Baseline information extracted from the medical records included age, sex, type of health insurance, and the number of GP visits during the 12 months before vaccination. Medical history data included diagnoses of lung disease (see Setting and Study Subjects) and the following diagnoses of high risk cardiac comorbidity 26 : angina pectoris, myocardial infarction, other chronic ischaemic heart disease, heart failure, atrial fibrillation/flutter, paroxysmal tachycardia, ectopic beats, pulmonary heart disease, heart valve disease, other heart disease, and pulmonary embolism. Study outcomes were all cause death, exacerbation of pre-existent lung disease, pneumonia, congestive heart failure, acute myocardial infarction, and angina pectoris in week 46 (1995) to week 12 (1996) . 10-14 29 30 Acute low respiratory tract illness (LRTI), including pneumonia and 70 (15) 320 (26) * Compulsory for patients with income lower than £21.50. † In this category patients with pleurisy, other unspecified neoplasm lung, congenital anomalies, and other diseases of respiratory tract only are included (n=23). ‡ Chronic obstructive pulmonary disease (in this category patients with neoplasm of lar/trac/bron/lung only are included, n=20). § ICPC codes K74-80, K82-84, K93 (see also data collection). exacerbations, was defined as the presence of one or more of the following signs/symptoms presented to the GP: (1) productive cough, (2) wheezy breathing or (3) increased dyspnoea in rest which led to the prescription of antibiotics, 2 agonists or corticosteroids. Additional information included hospitalisation, length of hospital stay, and use of intensive care facilities. All medical data were checked in the medical records by a physician in April 1996.
STATISTICAL ANALYSIS
We dichotomised age into 18-64 or >65 years (retirement age) 1 and underlying lung disease into COPD or asthma. 9 We combined the outcomes all cause death, acute LRTI, and cardiac disease (CD) to form the primary outcome measure. The two subsidiary outcome measures were any acute LRTI or CD. Univariate analyses were performed to compare vaccinees and non-vaccinees in baseline characteristics using 2 tests for categorical variables and Student's t test for continuous variables. Multivariable logistic regression modelling (with EGRET) was used to obtain adjusted estimates and their 95% confidence intervals of vaccine eVectiveness. 10 14 31 In the first stage of constructing the model we defined the dependent variable as presence or absence of the primary outcome and the exposure term as vaccination status. We allowed for the potentially confounding variables age, sex, health insurance, lung disease defined as asthma or COPD, presence or absence of cardiac comorbidity, and number of GP visits in the previous 12 months and simultaneously added first order interaction terms of these variables with vaccination status and age. At this stage it became evident that the interaction term age by vaccination status contributed statistically significant to the model, whereas other interaction terms did not. We proceeded by constructing two separate models for both age categories separately.
In the final models we only included those variables that substantially changes the estimate of vaccine eVectiveness. Regression diagnostics, including distributional and residual plots, and assessment of outliers were used to assess the robustness of the models. EVectiveness was estimated using the formula: (1−OR)×100%. 11 We calculated MantelHaenszel weighted relative risks (with EPIInfo) to verify estimates using odds ratios with frequent outcomes.
ECONOMIC ANALYSIS
We estimated direct costs of vaccination and combined average costs of hospital stay and use of intensive care facilities from a societal perspective. Net savings were estimated as follows: net savings= immunisation costs (including unit costs of vaccines and supplies, promotion, delivery, vaccination, and overhead)− costs of medical care averted. The number of outcomes averted was calculated as follows: (N vaccinees) × (attack rate of outcomes among non-vaccinees) × (eVectiveness). 11 Immunisation costs were estimated at £12.50 per person, including supplies, promotion, delivery, vaccination, and overhead. The estimation was based on the total expenses of vaccination that could be claimed by GPs in 1995. Expenses were based on unit costs of vaccine (£4.60) and delivery (£3.60), and £12.90 for patients with private insurance, which equals £4.30 on average for all patients. Costs of expenses (or charges) were comparable with direct costs to society. Costs of hospital stay (£168/day) and intensive care facilities (£821/day) were based on national data. 32 To assess the eVects of various estimates on the outcome of the economic analysis, an optimal and worst case scenario were established. We simultaneously varied estimates of eVectiveness, proportion of patients needing medical care, and median length of hospital stay over a plausible range of plus or minus 20 per cent.
Results
The overall influenza vaccination rate in the 1696 study subjects was 73%. Age specific immunisation rates were 66 (18-64 years) and 85% (>65 years). At baseline, vaccinees were older (57 compared with 47 years, t value 10.5, p<0.001), more often female, and insured through the Sick Fund than non-vaccinees. Also, COPD, cardiac comorbidity, and a high GP visiting rate were more common among vaccinees (table 1) .
Overall, the attack rate of any complication was 15%, mainly due to LRTI (14%). Exacerbations of underlying lung disease were most frequently observed (12.7%). The occurrence of death (0.5%), CD (1.3%), and pneumonia (1.3%) was less frequent. The recorded primary cause of death was cardiac heart failure (3), pneumonia (2), pneumothorax, cachexia, and ileus (n=8).
In patients aged 18-64 years, the attack rate of any complication in vaccinees was slightly higher than in non-vaccinees (table 2) . Acute CD and pneumonia were rarely observed, and no deaths occurred. In contrast, the occurrence of any complication in the elderly (>65 years) was substantially higher, although less common in vaccinees than in non-vaccinees (21 compared with 32%). Table 3 shows the results of the multivariable analyses. In patients aged 18-64 years, no eVectiveness of the immunisation programme in reducing the occurrence of any complication could be established, after adjustment for the prognostic confounding variables underlying lung disease, cardiac comorbidity, and number of GP visits (adjusted OR 0.95, 95% CI 0.62, 1.48, table 3). The inclusion of the other baseline variables age, sex, and health insurance did not confound the association between outcomes and vaccination status. Vaccination in the elderly (>65 years) was associated with a substantial reduction of the occurrence of any complication (50%), any acute LRTI (46%), or CD (57%, not statistically significant) after adjustments. In patients with cardiac comorbidity (n=197), the eVectiveness in preventing acute CD amounted even to 80% (95% CI 32 to 98%, data not shown).
In all, the hospitalisation rate was 1.8%. In 90% of hospitalised patients, one or more of the following risk factors was present: age over 65 years, COPD, cardiac comorbidity, or a high GP visiting rate. As vaccine eVectiveness could only be demonstrated in patients >65 years, we limited economic analyses to these subjects (table 4). The hospitalisation rate in elderly patients (including the deceased) with LRTI was 9.2% and 45% for elderly with CD. Median hospital stay due to LRTI was 10 days (range 5-20 days) with 1.7% in intensive care, while for CD it was 14 days (range 7-60 days) with 15% in intensive care. In the scenario analyses, we varied eVectiveness in preventing LRTI from 26 to 66% and CD from 37 to 77%. Hospitalisation rates due to LRTI were varied from 7.4 to 11% and CD from 36 to 54%, while median stay in hospital was varied from 8 to 12 days and from 12 to 16 days, respectively. After subtracting the mean vaccination costs, we estimated the net savings to be £50 (range from £16 to £101) per elderly vaccinee.
Discussion
The findings in this study suggest that influenza vaccination is eVective and costsaving in elderly patients with lung disease, but not in those aged under 65 years. However, some issues need to be considered. Confounding by indication is one of the important threats when studying intervention eVects using an observational design. As shown in our study, vaccinees were at higher risk of developing complications than non-vaccinees, which could have led to an underestimation of the vaccine eVectiveness. This confounding may therefore have obscured a potential benefit in the younger age group. Nevertheless, the immunisation rate of 66% was high compared with most other vaccination studies, [10] [11] [12] [13] [14] which probably reduces serious diVerences in baseline prognosis. Also, the study population was homogeneous with regard to indication criteria and the prevalence of lung disease (36 of 1000) was comparable with Dutch general practice morbidity registration data (30-40 of 1000). 26 33 Furthermore, we adjusted for some important prognostic confounding variables. The variable underlying lung disease was given by subdividing patients into asthmatic patients and COPD patients in accordance with other studies. 9 34 Misclassification of lung disease was most probably very limited, because participating GPs were extensively trained in classifying lung patients according to ICHPPC-2 criteria. Health seeking behaviour and seriousness of disease were also controlled for by the number of previous GP visits. 14 Nevertheless, we could only adjust for known diVerences in vaccinees and non-vaccinees. Complete comparability of vaccinees and non-vaccinees with regard to the prognosis of developing influenza related complications can only be guaranteed in a randomised placebo controlled trial.
We could not obtain valid information on previous vaccinations. Some reports suggest a reduced eVectiveness if patients are vaccinated for the first time. 16 17 As our GPs have been immunising lung patients against influenza since the early nineties, it is probable that most vaccinees had been vaccinated more often.
Another possible limitation, like in all other large eVectiveness studies, 10-15 17 18 includes the absence of laboratory confirmation of influenza. A sensitive and non-specific definition of clinical outcome may lead to an underestimation of the eVectiveness.
14 Although it has not been reported yet, specificity of outcome definitions may be higher in the elderly when compared with the younger age group. This might have contributed to the established diVerences in eVectiveness. Our finding of no eVectiveness in younger adults is in agreement with an earlier report by Wiselka and colleagues 3 who could not establish vaccine eVectiveness in preventing exacerbations in asthmatic patients aged 6 to 56 years during the 1989/90 epidemic. Most exacerbations in their study subjects were indeed thought to be caused by viruses other than influenza A. Beasley et al 27 concluded that only in one third of severe exacerbations in asthmatic patients aged 15-56 years could a viral agent be identified. The potential impact of an immunisation programme on the overall reduction of complications may be at stake when influenza is not the causal agent. Two other cost-benefit studies indicated no financial benefit from immunising patients under 65 with various medical conditions. 19 35 The authors attributed this to low death and hospitalisation rates in the younger age group during an influenza epidemic. We observed no deaths in patients under 65 and hospitalisation rates were 3.2 times lower in this group.
The inclusion of acute lung and heart disease as it presents to the GP in the primary outcome measure may be considered an important advantage of this study. The burden of illness could mainly be attributed to exacerbations of pre-existing lung disease (13%), whereas a minority of patients (2%) was hospitalised. Studies in which hospitalisation and death are the primary end points may suVer from more serious selection bias, because hospitalisation is mainly limited to patients with severe medical conditions as shown in our study.
The fact that all deceased persons were vaccinated reflects a high immunisation rate in the elderly subjects (85%). We were not able to confirm influenza as the primary cause of death, hence inferences about vaccination status and mortality are diYcult. 36 Our age specific death rate of 1.3% in the elderly was substantially lower than reported by Fleming et al 14 (3.0% in high risk elderly) and comparable to rates reported by Nichol et al 10 who included mostly healthy non-institutionalised elderly. Immunisation rates in these studies were lower than in our study (10% and 58%, respectively).
The estimated vaccine eVectiveness of 50% in the elderly is in accordance with a recently published large meta-analysis, 13 but net savings seemed to be higher than reported earlier. [10] [11] [12] As indirect costs resulting from work loss are less important in the elderly, we only calculated direct costs. 10 Furthermore, we decided not to add costs resulting from consultations for side eVects, because only few such consultations occurred in this study. Possible savings from the reduced number of GP consultations and drug use were even not taken into account. Accordingly, our estimates of net savings may be considered conservative.
Recently, Tirimanna and colleagues 34 showed that more than half the patients with asthma or COPD were not even known to the GP. Although screening on lung function was not part of this study, it is probable that elderly patients with unknown lung disease could also benefit from vaccination. An age based vaccination policy may increase the likelihood of reaching all elderly patients with known and unknown high risk medical conditions in the community. 21 Our study suggests that in the Netherlands the immunisation of elderly patients with chronic lung disease against influenza is eVective and cost-saving. A population based strategy should be developed so that these patients can be identified and immunised eYciently. 25 More, preferably experimental studies are needed to establish whether adult patients with lung disease under 65 years should be given priority as well.
+ The 1995/96 influenza epidemic was associated with a high attack rate of complications (15%) in patients with chronic lung disease. + Exacerbations of pre-existent lung disease were among the most frequent complications (13%). + In the Netherlands, the influenza vaccination seemed to be cost-saving in patients with chronic lung disease aged over 65 years. + This study gives no evidence for vaccine eVectiveness in adult patients with chronic lung disease under 65 years.
